[Executive summary of the guidelines on the diagnosis and treatment of acute heart failure].

By M. Nieminen, M. Böhm, Martin R Cowie, H. Drexler, Gerasimos Filippatos, G. Jondeau, Y. Hasin, J. López-Sendón, A. Mebazaa, M. Metra and 2 more. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2005

1,080 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/cd43aa54173c2609d9dc165570d4bb7710339556

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. (2007, methodology): “tivation, and hypotension.(21) As a consequence, physicians have to balance the need for aggressive diuresis against these potential adverse effects.”
Narrative Review (2012, background): “b-receptor agonists (eg, dobutamine) and phosphodiesterase III isoenzyme inhibitors (eg, milrinone) are currently recommended and are widely used in the treatment of patients with ADHF.(9,11) b-receptor agonists activate adenyl cyclase, increasing intracellular cyclic adenosine monophosphate (cAMP) ”
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006, background): “The ACC/AHA/NASPE 2002 Guidelines Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices (1), the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (2), the ESC 2001 and 2003 Guidelines on Prevention of Sudden Cardiac Death (3,4), the ES”
EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. (2006, methodology): “The primary objective of EuroHeart Failure Survey II (EHFS II) was to assess characteristics and management of AHF patients across Europe in relation to the guidelines on the diagnosis and treatment of AHF published by the European Society of Cardiology (ESC).(14) Specific issues addressed in this s”
Report from a consensus conference on primary graft dysfunction after cardiac transplantation. (2014, unknown): “58,59 D ’ Alessandro et al 6 retrospectively assessed the use of ECMO temporary support as a treatment for PGD.”
State of the art: Using natriuretic peptide levels in clinical practice (2008, methodology): “AxSYM BNP assay (central lab) becomes available 2005 PRIDE study on NT-proBNP in AHF published [17] 2005 ESC Guidelines for acute and chronic Heart Failure Endorse BNP [18, 19 ] 2006 Biosite Triage BNP Test receives CLIA waiver for whole blood use.”